The direct answer: NHS or private?

ChondroFiller is not available on the NHS. No NHS trust routinely funds it, and no commissioning pathway currently exists for the treatment anywhere in the UK — regardless of region, GP referral, or clinical need.

For UK patients who want ChondroFiller specifically, the only route is private treatment: either self-funded out of pocket or, in some circumstances, through private medical insurance. That position is consistent across every NHS region and is unlikely to change in the near term, as ChondroFiller has not yet entered a NICE technology appraisal.

The NHS does fund cartilage repair through other means — Autologous Chondrocyte Implantation (ACI) being the principal commissioned option — and private pricing for ChondroFiller follows a straightforward per-box structure. Understanding both helps patients decide which route suits their situation.

What the NHS does fund for cartilage repair

Autologous Chondrocyte Implantation (ACI) is the NHS-commissioned cell therapy for focal cartilage defects in the knee, having received NICE approval in 2017. It is available at a small number of specialist NHS centres across England — the Royal National Orthopaedic Hospital (RNOH) at Stanmore and University Hospital Southampton being two named sites. Spherox, a sphere-forming chondrocyte product, is also referenced as an NHS-funded option for eligible patients with suitable defect profiles.

Eligibility criteria apply for both. Referral for NHS ACI typically requires a confirmed focal chondral lesion, usually in the knee, and patients must meet clinical thresholds assessed at the specialist centre. Not everyone with cartilage damage will qualify.

The ACI pathway is substantively different from outpatient injection treatment. It involves two separate surgical procedures: a first operation to harvest a small cartilage biopsy, a laboratory stage lasting four to six weeks in which the patient's own chondrocytes are cultured, and a second operation to implant the expanded cells. Rehabilitation following reimplantation may extend to 12 months before a patient returns to full activity.

Neither ACI nor Spherox is the same technology as ChondroFiller. ACI uses the patient's own cultured chondrocytes; Spherox is a sphere-forming variant of that approach; ChondroFiller is an acellular collagen scaffold that works through a different mechanism — recruiting the body's own progenitor cells rather than supplying cultured donor cells. The distinction matters when patients are comparing their options, as the clinical journeys and recovery arcs differ considerably.

Why ChondroFiller is not yet NHS-commissioned

The CE mark ChondroFiller holds confirms it meets European safety and performance standards as a Class III medical device, but CE marking and NHS funding are separate regulatory questions. Market authorisation does not oblige any NHS trust to commission a treatment.

The standard gateway to routine NHS funding for a new medical technology is a NICE Technology Appraisal (TA). No NICE TA has been submitted or published for ChondroFiller, and there is no public indication that one is being pursued. Without a positive NICE recommendation — or an equivalent commissioner-led review — NHS trusts have no mechanism to fund the procedure routinely, even where a clinician considers it clinically appropriate for a specific patient.

The evidential requirements for NICE are also relevant here. NICE typically expects independent, peer-reviewed evidence when appraising a new technology. The published outcome data for ChondroFiller — including approximately 30-point improvements in IKDC knee scores at 12 months — derives substantially from manufacturer-sponsored studies, including the manufacturer's own April 2025 Clinical Evaluation Report. Independent replication would ordinarily be expected before a positive commissioning recommendation could be issued.

The gap between CE marking and NHS availability is therefore structural, not incidental. It reflects how the commissioning system functions for any novel device, and can persist for years even when early clinical results are encouraging.

How the private ChondroFiller pathway works

Accessing ChondroFiller privately follows a straightforward outpatient pathway. The treatment is delivered as an ultrasound-guided injection into the cartilage defect — no theatre admission, surgical incision, or general anaesthetic is involved. The collagen scaffold is placed under real-time image guidance during a single clinic appointment, after which the patient can leave the same day.

Once positioned within the defect, ChondroFiller gels in situ and acts as an acellular matrix. The mechanism is acellular matrix-induced chondrogenesis: rather than supplying donor cells, the scaffold recruits the patient's own progenitor cells from the surrounding synovium and subchondral bone, supporting the body's own repair processes from within the defect site.

The number of ChondroFiller boxes required depends on the size and location of the defect. Most focal cartilage defects are treated with a single box; larger or multi-site defects may require two or three. The treating specialist will assess this during the initial consultation, typically using MRI findings alongside clinical examination.

Private providers commonly bundle the consultation, ultrasound guidance, the implant itself, intravenous antibiotic cover administered at the time of the injection, and a follow-up appointment into a single all-inclusive fee. The exact scope of any package should be confirmed directly with the treating clinic before proceeding.

What private ChondroFiller treatment typically costs

Guide costs published by UK providers place the single-box ChondroFiller treatment — covering a single focal defect — at around £3,000, with two-box and three-box courses typically quoted at around £5,500 and £8,000 respectively. These figures represent all-inclusive packages: the implant, ultrasound-guided placement, IV antibiotic cover at the time of treatment, and a follow-up appointment are normally bundled into the headline price rather than itemised separately. Because most focal cartilage defects are treated with one box, the single-box guide cost is the figure most patients start their planning around.

Pricing can vary between providers and may change over time, so any figure found online should be treated as an orientation rather than a binding quote. Before committing, ask the clinic for a written breakdown that confirms whether the initial consultation is included or charged separately, and what happens if a second box is needed once the defect is assessed at the time of treatment. A clear written quote removes the risk of unexpected additions to the final bill.

Private medical insurance: what to check before you book

Before booking any private ChondroFiller appointment, contacting your insurer is the single most important administrative step. Coverage for ChondroFiller-based procedures is not automatic — where it exists at all, approval is granted on a case-by-case basis, and general policy descriptions rarely give a reliable answer.

One variable worth clarifying with your insurer is how the procedure will be classified. The way a treatment is coded and categorised — for example, as an outpatient injectable scaffold procedure versus a surgical cartilage intervention — can affect whether a given policy applies, even within the same insurer. Ask the clinic which CCSD or procedure codes they will use when billing, then confirm with your insurer that those exact codes are covered under your policy before you commit to a date.

Any agreement with your insurer should be obtained in writing. Verbal confirmation is not sufficient: written pre-authorisation is the standard that protects you if a dispute arises later. Insurer policies can also change between the time you enquire and the time of treatment, so check that the pre-authorisation remains valid close to the appointment date.

If insurance does not apply, self-funding remains the alternative for patients who are not eligible for, or do not wish to pursue, NHS ACI. Having a clear written quote from the clinic and written confirmation from your insurer — whatever the outcome — puts you in the strongest position to make that decision with full information.